Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

NCT01758328 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: busulfan
DRUG: melphalan
DRUG: fludarabine
BIOLOGICAL: anti-thymocyte globulin (ATG)
PROCEDURE: a T cell depleted stem cell transplant

Sponsor

Memorial Sloan Kettering Cancer Center